CHAPTERS
- 0:00 – 0:46
From a scheduling mishap to a global trauma mission
Joe explains how a last-minute change (and Duncan Trussell’s emergency root canal) turned the planned appearance into a one-on-one conversation. Rick Doblin arrives straight from Ukraine, framing the episode around trauma response and psychedelic-assisted therapy worldwide.
- 0:46 – 3:54
Ukraine: training clinicians amid war and restrictive drug laws
Doblin describes training 55 Ukrainian psychiatrists and therapists in Lviv while air-raid sirens blare in the background. He highlights Ukraine’s enormous trauma burden and the legal barriers that still prevent Schedule I research there.
- 3:54 – 4:49
Taking the model to Beirut and other under-resourced trauma zones
Doblin outlines plans to speak in Lebanon and explore the possibility of initiating MDMA research there. He clarifies he’s speaking personally (not for MAPS or Lykos) and emphasizes philanthropy as the near-term engine for global expansion.
- 4:49 – 6:11
Why progress feels so slow: MDMA’s path from 1982 to criminalization
Joe presses on the “snail’s pace” of acceptance, and Doblin traces the arc from his first MDMA experience in 1982 through its 1985 emergency scheduling. They discuss how MDMA moved from therapy circles to “ecstasy” club culture, accelerating backlash.
- 6:11 – 9:10
Celebrity culture, psychedelics, and changing minds (Larry Hagman stories)
A tangent becomes a point: public figures can normalize psychedelic benefits. Doblin shares how Larry Hagman’s LSD therapy experience and public comments helped shift perceptions—and how relationships like these supported MAPS.
- 9:10 – 14:21
MAPS origin story and the DEA legal battle: winning twice, losing the war
Doblin explains how administrative and appeals-court fights shaped MAPS’s strategy: the DEA wouldn’t make MDMA a medicine, so they had to go through the FDA. He also recounts the revelation that the initial emergency scheduling was procedurally invalid.
- 14:21 – 18:57
Drug war harms and policy whiplash: from ‘crack babies’ panic to Portland
Doblin uses his father’s pediatric research to show how stigma and criminalization push people away from help. Joe and Rick debate the pitfalls of localized decriminalization—Portland and Zurich’s “Needle Park”—and why humane approaches must be scalable and structured.
- 18:57 – 21:30
Bridges to the mainstream: military/veterans, ibogaine, and bipartisan credibility
They argue that veterans and conservative leaders can function as cultural “bridges” that de-stigmatize psychedelics. Rick Perry, Brian Hubbard, and Morgan Luttrell become examples of how trauma recovery stories translate into political momentum.
- 21:30 – 25:38
What makes psychedelic therapy work: set/setting, integration, and neuroplasticity
Doblin emphasizes that clinics must pair compounds with skilled therapy, preparation, and integration—contrasting with many ketamine clinics that skip therapy. He introduces the neuroscience angle: psychedelics reopening “critical periods” of plasticity where lasting change is more achievable.
- 25:38 – 40:01
Non-psychedelic psychedelics in practice: cluster headaches and Bromo-LSD
Doblin tells the origin story of Cluster Busters and early evidence that LSD/psilocybin can interrupt cluster headache cycles. Attempts to avoid stigma led researchers to test Bromo-LSD—only to find it worked even better—yet funding and regulatory inertia still block widespread access.
- 40:01 – 54:11
Ceremony, rites of passage, and how culture shapes outcomes
The conversation shifts to how societies integrate altered states responsibly—ayahuasca churches, the Native American Church, and ceremonial use even among youth. Doblin recounts how his bar mitzvah felt like a failed rite of passage, and how LSD later provided the transformative ‘threshold’ experience he expected.
- 54:11 – 1:07:18
Scaling treatment: VA timelines, couples work, and the move toward group MDMA therapy
Doblin details how long it took to get MDMA therapy into the VA, then explains why couples-based approaches can outperform individual-only models. With PTSD at population scale, he describes emerging research on group therapy models (VA, Australia, Israel) and the tradeoffs between depth and peer-supported integration.
- 1:07:18 – 1:23:28
FDA rejection, the double-blind problem, and what approval could take next
Doblin explains why MDMA-assisted therapy was not approved despite strong Phase 3 outcomes: concerns about functional unblinding, bias, and trial design communication failures. He lays out the fork ahead—possible near-term approval with post-marketing requirements vs a new Phase 3 trial that could add years.
- 1:23:28 – 1:34:42
Why Doblin kept going: a guiding dream, privilege as obligation, and consciousness vs catastrophe
Doblin shares a formative dream linking Holocaust survival, human dehumanization, and the mission to restore psychedelics as tools for empathy and interconnectedness. He reflects on using privilege for long-term change and frames the moment as a race between expanding consciousness and technological catastrophe.
- 1:34:42 – 2:08:54
Suppression through history, shadow projection, and the importance of context
They connect modern drug policy to centuries of suppression—Eleusinian Mysteries, gatekeeping institutions, colonial crackdowns—and discuss why psychedelics aren’t automatically ‘good’ without context. Doblin ties in Jung’s concept of shadow projection and recounts intense DMT/ketamine insights about collective responsibility and mass psychology.
- 2:08:54 – 2:14:11
Psychedelic Science 2025: conference details, global access, and closing reflections
Doblin previews Psychedelic Science 2025 in Denver: hundreds of speakers, multiple stages, music programming, and networking across the psychedelic ecosystem. They close by discussing inclusion of law enforcement and international work in trauma zones, ending on persistence and long-term, multi-generational goals.
